Asia-Pacific At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine percent, certainly its most dynamic. Chronic underfunding of healthcare systems in APAC means that a region accounting for 60 percent of the world’s population only represents a quarter of global…

MEA The latest news from Middle East & North African pharma, including Pfizer’s transformation of its Saudi operations; why India is calling for reform of the import process for pharma products in the Arab world; Hikma’s buyup of GSK assets in Egypt and Tunisia; and Tabuk’s biosimilar distribution deal.   Pfizer…

USA With Rare Disease Day coming up on February 28th, one of the leading organizations dedicated to serving affected patients in the US, the National Organization for Rare Disorders (NORD), is making a push to put the spotlight on the limited access to diagnosis, treatment and care suffered by rare disease…

Global As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Over the last few decades, while big pharma companies continued to focus on their core business, contract development and manufacturing organizations (CDMOs) have positioned themselves as alternatives to in-house development and manufacturing operations, promising to decrease…

Germany After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into public opinion on healthcare   STADA, based in Bad Vilbel, focuses on a two-pillar strategy consisting of generics, including specialty…

USA The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar medicines have on US healthcare today and introduces the ‘Secure Our Meds’ campaign which aims to educate policymakers on the importance of generic and biosimilar market competition and how it can be safeguarded.   More than 35 years…

Global Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights the incredible progress of COVID-19 vaccines from bench to market in less than a year and introduces the IFPMA’s new #TeamVaccines campaign, shedding light on the personal stories behind this miraculous effort.   The story of COVID-19…

Global One of the more intriguing aspects about the new wave of cell and gene therapies (CGT) coming onstream is that they are not just technologically innovative in terms of the sheer novelty of the medical science, but they are also serving to upend the traditional operating model of the pharma…

USA Following on from our profile on five of the most promising clinical-stage biotech companies developing orphan therapies in Europe, here we move to the world’s biggest biopharmaceutical market and R&D hub, shining the spotlight on five of the most important and innovative rare-disease start-ups in the USA.   The US…

China HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T: advanced degrees in different scientific fields, including a master’s in microbial engineering and chemical engineering and a PhD in molecular biology and genetics, an academic career at top US institutions…

Europe Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler of Sanofi R&D looks at the future of European pharma post-Brexit, with the UK diverging from the rest of the continent in regulatory terms and the launch of the European Commission’s Pharmaceutical Strategy for Europe.   After four…

China Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi Wang from the Shanghai Center for Drug Evaluation & Inspection analyse the Chinese NMPA’s drug approval list for 2020, including a surge in approvals for locally developed drugs.   In the…